Table 4.
Characteristics associated with BCSS and DFS by multivariate analysis in patients in the training set.
| Multivariate Analysis | BCCS | p-value | Multivariate Analysis | DFS | p-value |
|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | ||||
| BMI (kg/m2) | 1.08 (0.94–1.24) | 0.27 | Age | 0.96 (0.93–0.999) | 0.04* |
| Comorbidities | 7.65 (0.85–68.61) | 0.07 | Comorbidities | 7.13 (1.49–34.06) | 0.01* |
| Side | 1.66 (0.74–3.73) | 0.21 | Multi-focal | 2.51 (0.93–6.78) | 0.07 |
| Bilateral malignant tumor | 6.00 (1.87–19.27) | 0.003* | Bilateral malignant tumor | 3.43 (1.51–7.80) | 0.003* |
| Pregnancy post-op | 4.95 (0.56–43.89) | 0.15 | Pregnancy post-op | 3.56 (0.78–16.32) | 0.10 |
| Grade | Hormonal receptor | 3.45 (0.11–1.10) | 0.07 | ||
| I | 1.00 | Grade | |||
| II | 0.86 (0.11–6.93) | 0.89 | I | 1.00 | |
| III | 1.49 (0.18–12.49) | 0.71 | II | 1.08 (0.26–4.51) | 0.91 |
| AJCC stage | III | 1.18 (0.26–5.40) | 0.83 | ||
| I | 1.00 | AJCC stage | |||
| II | 1.13 (0.28–4.53) | 0.86 | I | 1.00 | |
| III | 2.03 (0.43–9.59) | 0.37 | II | 12.10 (0.97–4.55) | 0.06 |
| Number of positive nodes | 1.02 (0.93–1.10) | 0.59 | III | 3.12 (1.14–8.52) | 0.03* |
| LVI | 2.57 (1.03–6.40) | 0.04* | Number of positive nodes | 1.05 (1.004–1.11) | 0.03* |
| Her-2 status | LVI | 1.54 (0.78–3.08) | 0.22 | ||
| 0–1+/FISH(−) | 1.00 | Lipo-filling | 1.26×10−7 (0–Inf) | 0.99 | |
| 2+ | 1.77 (0.57–5.54) | 0.33 | Radiation | 1.42 (0.73–2.77) | 0.30 |
| 3+/FISH(+) | 2.03 (0.68–6.06) | 0.20 | Hormonal therapy | ||
| Unknown | 0.47 (0.14–1.56) | 0.22 | No | 1.00 | |
| Ki-67 | Yes | 2.92 (0.91–9.46) | 0.07 | ||
| <15% | 1.00 | Unknown | 9.23 (0.09–9.84) | 0.95 | |
| ≥15% | 1.61 (0.20–13.20) | 0.65 | |||
| Unknown | 3.82 (0.47–30.97) | 0.21 | |||
| Radiation | 4.78 (1.67–13.68) | 0.004* | |||
| Type of reconstruction (autologous vs. implant-based) |
1.70 (0.65– 4.42) | 0.27 |
BMI, Body mass index; LVI, Lymphovascular invasion; Inf, Infinity. *p < 0.05.